Thus, the presenceof anti-PGL-III could be a biomarker of the “leprosy reaction”.Since PGL-III is uniquely recognized by Mincle to exert its potentdose-dependent activity (Figure 3c), the concept of Mincle antagonists that interferewith PGL-III binding while not interfering with the recognition ofother Mincle ligands is a promising chemical approach to suppressingthe hyperimmune response observed during the leprosy reaction. Here, CLEC4E is linked to leprosy.